Depending on the timing of market entry, radical innovations can be distinguished from incremental innovations. Whereas a radical innovation typically is the first available derivative of a drug class, incremental innovations are launched later and show a certain benefit compared with the radical innovation. Here, we use historical market data relating to pharmacokinetic (PK), pharmacodynamic (PD), and other drug-related properties to investigate which derivatives within certain drug classes have been most successful on the market. Based on our investigations, we suggest naming the most successful drugs ‘overtaking innovation’, because they often exceed the market share of all the other derivatives. Seven drug classes showed that the overtaking innovation is never a radical innovation, but rather an early incremental innovation, with advantages in manageability and/or tolerance.

根据进入市场的时间，可以将激进创新与增量创新区分开。根本性创新通常是药物类别中第一个可用的派生产品，而增量性创新则在稍后推出，并且与根本性创新相比具有一定的优势。在这里，我们使用与药代动力学（PK），药效学（PD）和其他药物相关特性有关的历史市场数据来调查某些药物类别中的哪些衍生物在市场上最成功。根据我们的调查，我们建议将最成功的药物命名为“超越创新”，因为它们经常超过所有其他衍生物的市场份额。七个药物类别显示，超越的创新绝不是彻底的创新，而是早期的渐进式创新，